![PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg. - ppt download PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg. - ppt download](https://slideplayer.com/15075835/91/images/slide_1.jpg)
PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg. - ppt download
![Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review - International Journal of Cardiology Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review - International Journal of Cardiology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/f5e68b67-b08c-4cfd-8b3a-73d5c9b918ab/gr1.jpg)
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review - International Journal of Cardiology
![Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V. - ppt video online download Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V. - ppt video online download](https://slideplayer.com/slide/4583435/15/images/5/Primary+composite+outcome.jpg)
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V. - ppt video online download
![Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial - The Lancet Diabetes & Endocrinology Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial - The Lancet Diabetes & Endocrinology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/49faccc3-5e5a-4c3d-8d03-39f561de3429/gr1_lrg.jpg)
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial - The Lancet Diabetes & Endocrinology
![Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis | JACC: Heart Failure Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis | JACC: Heart Failure](https://www.jacc.org/cms/asset/c9b5134d-8a3c-4016-9d3d-9d9796a9ca65/fx1.jpg)
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis | JACC: Heart Failure
![Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women - ScienceDirect Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109718389794-fx1.jpg)
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women - ScienceDirect
![Frontiers | Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum Frontiers | Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum](https://www.frontiersin.org/files/Articles/652163/fphys-12-652163-HTML/image_m/fphys-12-652163-g001.jpg)